Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9494044rdf:typepubmed:Citationlld:pubmed
pubmed-article:9494044lifeskim:mentionsumls-concept:C0330390lld:lifeskim
pubmed-article:9494044lifeskim:mentionsumls-concept:C0019046lld:lifeskim
pubmed-article:9494044lifeskim:mentionsumls-concept:C0040005lld:lifeskim
pubmed-article:9494044lifeskim:mentionsumls-concept:C0301715lld:lifeskim
pubmed-article:9494044lifeskim:mentionsumls-concept:C1979844lld:lifeskim
pubmed-article:9494044lifeskim:mentionsumls-concept:C0525038lld:lifeskim
pubmed-article:9494044lifeskim:mentionsumls-concept:C0425245lld:lifeskim
pubmed-article:9494044lifeskim:mentionsumls-concept:C2003941lld:lifeskim
pubmed-article:9494044lifeskim:mentionsumls-concept:C2698172lld:lifeskim
pubmed-article:9494044lifeskim:mentionsumls-concept:C1708533lld:lifeskim
pubmed-article:9494044lifeskim:mentionsumls-concept:C0673056lld:lifeskim
pubmed-article:9494044pubmed:issue1lld:pubmed
pubmed-article:9494044pubmed:dateCreated1998-4-16lld:pubmed
pubmed-article:9494044pubmed:abstractTextHb Godavari [alpha 95(G2)Pro-->Thr] was characterized independently in two families of different ethnic origin. The first case, found in the Netherlands, involved an Indian patient. The second one was identified a few months later in an African family from Mali, living in France. Hb Godavari is the fourth example of a substitution involving neutral residues at position alpha 95(G2). In all these variants the electrophoretic pattern suggested that the structural modification unmasks a charged residue buried in the alpha 1 beta 2 contact area. The oxygen affinity of this abnormal hemoglobin was approximately 10% higher than that of Hb A; in the absence of 2,3-diphosphoglycerate, its cooperativity was moderately decreased, suggesting a slightly unstable T state.lld:pubmed
pubmed-article:9494044pubmed:languageenglld:pubmed
pubmed-article:9494044pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9494044pubmed:citationSubsetIMlld:pubmed
pubmed-article:9494044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9494044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9494044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9494044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9494044pubmed:statusMEDLINElld:pubmed
pubmed-article:9494044pubmed:monthJanlld:pubmed
pubmed-article:9494044pubmed:issn0363-0269lld:pubmed
pubmed-article:9494044pubmed:authorpubmed-author:WajcmanHHlld:pubmed
pubmed-article:9494044pubmed:authorpubmed-author:GirotRRlld:pubmed
pubmed-article:9494044pubmed:authorpubmed-author:RiouJJlld:pubmed
pubmed-article:9494044pubmed:authorpubmed-author:NayuduN VNVlld:pubmed
pubmed-article:9494044pubmed:authorpubmed-author:GiordanoP CPClld:pubmed
pubmed-article:9494044pubmed:authorpubmed-author:KisterJJlld:pubmed
pubmed-article:9494044pubmed:authorpubmed-author:GalactérosFFlld:pubmed
pubmed-article:9494044pubmed:authorpubmed-author:Maier-Redelsp...lld:pubmed
pubmed-article:9494044pubmed:issnTypePrintlld:pubmed
pubmed-article:9494044pubmed:volume22lld:pubmed
pubmed-article:9494044pubmed:ownerNLMlld:pubmed
pubmed-article:9494044pubmed:authorsCompleteYlld:pubmed
pubmed-article:9494044pubmed:pagination11-22lld:pubmed
pubmed-article:9494044pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:9494044pubmed:meshHeadingpubmed-meshheading:9494044-...lld:pubmed
pubmed-article:9494044pubmed:meshHeadingpubmed-meshheading:9494044-...lld:pubmed
pubmed-article:9494044pubmed:meshHeadingpubmed-meshheading:9494044-...lld:pubmed
pubmed-article:9494044pubmed:meshHeadingpubmed-meshheading:9494044-...lld:pubmed
pubmed-article:9494044pubmed:meshHeadingpubmed-meshheading:9494044-...lld:pubmed
pubmed-article:9494044pubmed:meshHeadingpubmed-meshheading:9494044-...lld:pubmed
pubmed-article:9494044pubmed:meshHeadingpubmed-meshheading:9494044-...lld:pubmed
pubmed-article:9494044pubmed:meshHeadingpubmed-meshheading:9494044-...lld:pubmed
pubmed-article:9494044pubmed:meshHeadingpubmed-meshheading:9494044-...lld:pubmed
pubmed-article:9494044pubmed:meshHeadingpubmed-meshheading:9494044-...lld:pubmed
pubmed-article:9494044pubmed:meshHeadingpubmed-meshheading:9494044-...lld:pubmed
pubmed-article:9494044pubmed:meshHeadingpubmed-meshheading:9494044-...lld:pubmed
pubmed-article:9494044pubmed:meshHeadingpubmed-meshheading:9494044-...lld:pubmed
pubmed-article:9494044pubmed:meshHeadingpubmed-meshheading:9494044-...lld:pubmed
pubmed-article:9494044pubmed:meshHeadingpubmed-meshheading:9494044-...lld:pubmed
pubmed-article:9494044pubmed:meshHeadingpubmed-meshheading:9494044-...lld:pubmed
pubmed-article:9494044pubmed:year1998lld:pubmed
pubmed-article:9494044pubmed:articleTitleHb Godavari [alpha 95(G2)Pro-->Thr]: a neutral amino acid substitution in the alpha 1 beta 2 interface that modifies the electrophoretic mobility of hemoglobin.lld:pubmed
pubmed-article:9494044pubmed:affiliationINSERM U91 and Department of Biochemistry, Hôpital Henri Mondor, Créteil, France.lld:pubmed
pubmed-article:9494044pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9494044pubmed:publicationTypeCase Reportslld:pubmed
entrez-gene:3039entrezgene:pubmedpubmed-article:9494044lld:entrezgene